OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
774958

Medikit Co Ltd

Medical Equipment, Supplies & DistributionVerified

Medikit Co Ltd maintains a strong liquidity position, with a current ratio of 5.4 and cash and equivalents amounting to ¥21,559,317,000, which is significantly higher than the typical liquidity requirements for its industry. The company's debt-to-equity ratio is 0.02, indicating a conservative capital structure with minimal reliance on debt financing. The company's profitability is robust, with a return on equity (ROE) of 6.67% and a return on assets (ROA) of 5.74%. These figures are well above the industry median for medical equipment firms, suggesting that Medikit is effectively utilizing its equity and assets to generate returns. Medikit's revenue is primarily concentrated in Japan, with no disclosed international segments. The company's business is centered on the production and sale of medical equipment, with no material diversification across product lines or geographic regions. This concentration may expose the company to regional economic or regulatory risks. The company's growth trajectory is stable, with revenue of ¥22,553,238,000 in the latest reporting period. While no specific forward-looking guidance is provided, the company's operating cash flow of ¥3,629,192,000 and free cash flow of -¥475,144,000 suggest that it is generating sufficient cash to support operations, though capital expenditures are currently outpacing free cash flow. Risk factors for Medikit include the potential for regulatory changes in the healthcare sector, which could impact product approvals or market access. The company's low dilution risk and strong liquidity position mitigate some of these concerns, but the absence of a detailed risk management strategy in disclosed filings remains a gap. Recent events include the company's latest financial results, which show a net income of ¥3,013,544,000 and operating income of ¥4,485,379,000. No significant new product launches or strategic acquisitions were disclosed in the latest filings, and the company's capital expenditure of -¥3,849,637,000 indicates ongoing investment in infrastructure.

30-day price · 7749(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyMedikit Co Ltd
Ticker7749.T
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Medikit Co Ltd develops, manufactures, and sells medical equipment, including artificial diagnostic equipment, indwelling needles for dialysis, and angiography equipment.

Classification. Medikit Co Ltd is classified in the Healthcare Services & Equipment business sector under the Medical Equipment, Supplies & Distribution industry with a confidence level of 0.92.

Medikit Co Ltd maintains a strong liquidity position, with a current ratio of 5.4 and cash and equivalents amounting to ¥21,559,317,000, which is significantly higher than the typical liquidity requirements for its industry. The company's debt-to-equity ratio is 0.02, indicating a conservative capital structure with minimal reliance on debt financing. The company's profitability is robust, with a return on equity (ROE) of 6.67% and a return on assets (ROA) of 5.74%. These figures are well above the industry median for medical equipment firms, suggesting that Medikit is effectively utilizing its equity and assets to generate returns. Medikit's revenue is primarily concentrated in Japan, with no disclosed international segments. The company's business is centered on the production and sale of medical equipment, with no material diversification across product lines or geographic regions. This concentration may expose the company to regional economic or regulatory risks. The company's growth trajectory is stable, with revenue of ¥22,553,238,000 in the latest reporting period. While no specific forward-looking guidance is provided, the company's operating cash flow of ¥3,629,192,000 and free cash flow of -¥475,144,000 suggest that it is generating sufficient cash to support operations, though capital expenditures are currently outpacing free cash flow. Risk factors for Medikit include the potential for regulatory changes in the healthcare sector, which could impact product approvals or market access. The company's low dilution risk and strong liquidity position mitigate some of these concerns, but the absence of a detailed risk management strategy in disclosed filings remains a gap. Recent events include the company's latest financial results, which show a net income of ¥3,013,544,000 and operating income of ¥4,485,379,000. No significant new product launches or strategic acquisitions were disclosed in the latest filings, and the company's capital expenditure of -¥3,849,637,000 indicates ongoing investment in infrastructure.
Key takeaways
  • Medikit Co Ltd has a strong liquidity position with a current ratio of 5.4 and significant cash reserves.
  • The company's ROE of 6.67% and ROA of 5.74% indicate strong profitability relative to industry peers.
  • Revenue is concentrated in Japan, with no material international diversification.
  • The company is investing in capital expenditures, which may support long-term growth.
  • Medikit faces low dilution risk and has no immediate liquidity concerns.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyJPY
Revenue$22.55B
Gross profit$8.67B
Operating income$4.49B
Net income$3.01B
R&D
SG&A
D&A
SBC
Operating cash flow$3.63B
CapEx-$3.85B
Free cash flow-$475.1M
Total assets$52.47B
Total liabilities$7.31B
Total equity$45.16B
Cash & equivalents$21.56B
Long-term debt$759.8M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$45.16B
Net cash$20.80B
Current ratio5.4
Debt/Equity0.0
ROA5.7%
ROE6.7%
Cash conversion1.2%
CapEx/Revenue-17.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 5 companies
Metric7749Activity
Op margin19.9%13.3% medp25 5.9% · p75 13.5%top quartile
Net margin13.4%8.6% medp25 2.7% · p75 12.7%top quartile
Gross margin38.4%64.0% medp25 60.1% · p75 65.6%bottom quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-17.1%3.0% medp25 2.7% · p75 4.5%bottom quartile
Debt / equity2.0%69.3% medp25 63.4% · p75 74.5%bottom quartile
Observations
IR observations
Last actual EPS204.55 JPY
Last actual revenue22,553,240,000 JPY
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 16:21 UTC#75a8ca24
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 16:23 UTCJob: 86672eda